Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Engerix B

Engerix B

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Engerix B

33 trials tracked of Engerix B: 25 in phase 3 or 4 and 3 with published results. The most-cited published study has 36 citations.

33Trials tracked
25Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 12 Phase 3 13 Phase 2 5 Phase 1 2 Other / NA 1
  1. Phase 3 B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B Completed · 36 cited
  2. Phase 3 A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults Completed · 12 cited
  3. Phase 3 Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B® Completed · 10 cited
  4. Phase 4 Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B Completed
  5. Phase 4 Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children Completed
  6. Phase 4 Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult Completed
Show 27 more trials
  1. Phase 4 Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult Completed
  2. Phase 4 LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers Completed
  3. Phase 4 Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine. Completed
  4. Phase 4 Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine Completed
  5. Phase 4 Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination Completed
  6. Phase 4 Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine Completed
  7. Phase 4 Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc Completed
  8. Phase 4 Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers Completed
  9. Phase 4 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents Completed
  10. Phase 3 Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients Completed
  11. Phase 3 Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants Completed
  12. Phase 3 Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine Completed
  13. Phase 3 Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants Completed
  14. Phase 3 Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC Completed
  15. Phase 3 Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine Completed
  16. Phase 3 Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects Completed
  17. Phase 3 Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine Completed
  18. Phase 3 COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine Completed
  19. Phase 3 Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants Completed
  20. Phase 2 Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region Completed
  21. Phase 2 Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine Completed
  22. Phase 2 Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants Completed
  23. Phase 2 Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine Completed
  24. Phase 2 Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Completed
  25. Phase 1 Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults Completed
  26. Phase 1 Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali Completed
  27. N/A A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada Completed

Showing the 33 most-cited and recently-updated of 33 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.